Physician profile
Saeed Ahmed
NPI 1235228776
$14,201.37
in general payments reported to CMS, 2019-2025
53 companies · $3,832 in 2025
The $3,832 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $561 · 2021: $1,139 · 2022: $1,233 · 2023: $2,898 · 2024: $3,895 · 2025: $3,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,373 · Travel and Lodging: $1,217 · Education: $34.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,373.42 |
| Travel and Lodging | $1,217.15 |
| Education | $34.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,097.82 | 2019-2025 | Linzess, Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,923.25 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $843.77 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $815.12 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Medtronic, INC. | $798.91 | 2021-2025 | Endoflip, Nexpowder, Dragonfly Pancreaticobiliary Scope and Instrument Channel Caps |
| Olympus America INC. | $764.28 | 2024 | Evis X1 Video System Center |
| Pfizer INC. | $583.14 | 2019-2025 | |
| Celgene Corporation | $581.84 | 2021-2024 | Zeposia |
| Lumendi LLC | $452.87 | 2024 | |
| Ardelyx, INC. | $388.10 | 2023-2025 | Ibsrela |
| Boston Scientific Corporation | $333.98 | 2021-2025 | Axios, Exalt Model D, Axonics |
| Evoke Pharma, INC. | $296.41 | 2020-2025 | Gimoti |
| Phathom Pharmaceuticals, INC. | $231.95 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $220.92 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $218.64 | 2024-2025 | Omvoh |
Show all 52 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saeed Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.